Xenetic Biosciences (XBIO) Liabilities and Shareholders Equity (2011 - 2026)

Xenetic Biosciences (XBIO) has 16 years of Liabilities and Shareholders Equity data on file, last reported at $7.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 36.57% year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.7 million (down 10.34% YoY) and the FY2025 annual result came in at $8.4 million, up 21.19% from the prior year.
• Liabilities and Shareholders Equity slipped to $7.9 million in Q1 2026, from $8.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $18.0 million in Q1 2022 to a low of $5.1 million in Q3 2025.
• A 5-year average of $10.6 million and a median of $9.4 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity surged 52.9% — and 2025, when it slumped 40.73%.
• Tracing XBIO's Liabilities and Shareholders Equity over 5 years: stood at $14.7 million in 2022, then declined by 27.96% to $10.6 million in 2023, then sank by 34.92% to $6.9 million in 2024, then rose by 21.19% to $8.4 million in 2025, then slipped by 5.44% to $7.9 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $7.9 million (Q1 2026), $8.4 million (Q4 2025), and $5.1 million (Q3 2025), per Business Quant data.